Status:

TERMINATED

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

Lead Sponsor:

Senju Pharmaceutical Co., Ltd.

Collaborating Sponsors:

PPD Development, LP

Conditions:

Age-related Macular Degeneration

Eligibility:

All Genders

50+ years

Phase:

PHASE2

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelia...

Eligibility Criteria

Inclusion

  • Must agree to sign informed consent form, and to comply with protocol requirements, including study visits.
  • Must have clear optic media in the study eye that is capable of producing high-quality fundus images.

Exclusion

  • Has active CNV due to causes other than AMD in the study eye.
  • Has retinal vascular disease or retinal degeneration other than AMD in the study eye.
  • Has had intraocular surgery, cataract surgery or LASIK surgery on the study eye within 90 days prior to the study.
  • Has had yttrium aluminum garnet (YAG) laser capsulotomy on the study eye within 30 days prior to the study.
  • Has active inflammation, infection, or other severe ocular disease in either eye.
  • Has aphakia in the study eye.
  • Has uncontrolled glaucoma or a history of previous glaucoma filter surgery in either eye.
  • Is a contact lens wearer and is unable to discontinue their use in both eyes for the duration of the study.
  • Has a serious allergy to, or experienced a prior significant adverse reaction to fluorescein angiography (FA) or indocyanine green angiography (ICGA).
  • Has participated in any other clinical trial and/or has taken any investigational drug or product within 90 days prior to the study.
  • Other protocol-defined inclusion/exclusion criteria could apply.

Key Trial Info

Start Date :

February 25 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 24 2020

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT03869684

Start Date

February 25 2019

End Date

April 24 2020

Last Update

April 20 2021

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Senju Investigational Site

Peoria, Arizona, United States, 85381

2

Senju Investigational Site

Phoenix, Arizona, United States, 85053

3

Senju Investigational Site

Pasadena, California, United States, 91107

4

Senju Investigational Site

Redlands, California, United States, 92374